deCODE biostructures, Inc., announces that it successfully met a development milestone under its agreement with InterMune via delivery of multiple small molecule fragments to a proprietary protein target. The structures represent novel chemotypes and provide new scaffolds for developing unique small molecule drugs. In connection with the achievement of this milestone, deCODE and InterMune agreed to extend their collaborative research agreement.
About deCODE biostructures
deCODE biostructures and its sister company deCODE chemistry (www.decodechembio.com) conduct collaborative drug discovery research using an integrated platform of structural biology and chemistry technologies. deCODE biostructures is one of the largest gene-to-structure contract research organizations in the US, with clients from all research sectors including pharmaceutical and biotechnology companies, academic and research institutions, and government agencies.